Recent Updates
Recently added Catalysts

PF-08166744

Phase 1

Undisclosed | Small Molecules | Other |Pfizer, Inc.|Trials Updated: Nov 12, 2026

PF-08166744 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment82

FDA Designations

No designations recorded

PF-08166744 clinical trials

PF-08166744 · 1 trial · 1 indication

Phase 1 1
NCT07933835A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.Healthy Participants
NOT YET_RECRUITING82 Analytics
PHASE1NOT YET_RECRUITING
A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.
Healthy Participants
NCT0793383582
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Clinical Laboratory Abnormalities
Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Vital Sign Abnormalities
Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Electrocardiogram (ECG) Abnormalities
Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

Secondary Endpoints

SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of PF-08166744
Day 1 through Day 113
SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of PF-08166744
Day 1 through Day 113
SAD (Part A): Maximum Observed Plasma Concentration (Cmax) of PF-08166744
Day 1 through Day 113
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Arm 1: PF-08166744EXPERIMENTALParticipants in Part A will receive a single ascending dose of PF-08166744 by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple ascending subcutaneous doses of PF-08166744 according to the assigned cohort.
Arm 2: PlaceboPLACEBO_COMPARATORParticipants in Part A will receive a single dose of placebo by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple subcutaneous doses of placebo according to the assigned cohort.

Interventions

NameTypeDescription
PF-08166744DRUGParticipants will receive a single dose of PF-08166744 by subcutaneous or intravenous administration.
PlaceboDRUGParticipants will receive a single dose of placebo by subcutaneous or intravenous administration.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Participants 18 to 65 years of age, inclusive. * Participants considered generally healthy based on medical evaluation. * Body mass index (BMI) of 16 to 32 kg/m². * Body weight greater than 50 kg. * Participants must meet protocol-defined reproductive requirements. * Participa...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT07933835NEW_TRIAL: changed
LOWNov 12, 2026NCT07933835NEW_TRIAL: changed

Explore more on BiopharmaWatch

Pfizer, Inc. (PFE)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track